Search results

Edison Open House

https://oxb.com/videos/edison-open-house

Analyst Presentation: Interim results for the six months ended 30 June 2017

https://oxb.com/webcasts-and-audios/analyst-presentation-interim-results-six-months-ended-30-june-2017

Analyst conference call: Oxford BioMedica and Bioverativ Collaboration

https://oxb.com/webcasts-and-audios/analyst-conference-call-oxford-biomedica-and-bioverativ-collaboration

Analyst conference call: Preliminary results for the year ended 31 December 2017

https://oxb.com/webcasts-and-audios/analyst-conference-call-preliminary-results-year-ended-31-december-2017

Analyst conference call: Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease

https://oxb.com/webcasts-and-audios/analyst-conference-call-oxford-biomedica-and-axovant-sciences-enter-8425-million

Analyst Presentation: Interim results for the six months ended 30 June 2018

https://oxb.com/webcasts-and-audios/analyst-presentation-interim-results-six-months-ended-30-june-2018

Webcast: Preliminary results for the year ended 31 December 2018

https://oxb.com/webcasts-and-audios/webcast-preliminary-results-year-ended-31-december-2018

Analyst Presentation: Interim results for the six months ended 30 June 2019

https://oxb.com/webcasts-and-audios/analyst-presentation-interim-results-six-months-ended-30-june-2019

Preliminary results for the year ended 31 December 2019

https://oxb.com/webcasts-and-audios/preliminary-results-year-ended-31-december-2019

Oxford Biomedica Preliminary Results 2019

https://oxb.com/webcasts-and-audios/oxford-biomedica-preliminary-results-2019

Pages